However, applying a conventional age-based testing threshold would have substantially reduced the number of patients identified. Restricting testing to patients diagnosed before age 50 would have ...
Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer. Theodore Wagener, PhD, founding ...
The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival ...
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on ...
The addition of carotuximab (ENV-105) to apalutamide (Erleada) significantly improved progression-free survival (PFS) ...
Firmonertinib is a highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical and uncommon ...
CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, ...
Rusfertide was approved by the FDA 1 for adults with polycythemia who require phlebotomy, based on results from the phase 3 ...
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...
In an interview with Targeted OncologyTM, Daniel Heng, MD, of the University of Calgary, discusses the recent FDA approval of belzutifan (Welireg) plus lenvatinib (Lenvima) for patients with advanced ...
Among 102 patients with recurrent or metastatic head and neck squamous cell carcinoma evaluable for response, Dr Swiecicki reports a confirmed overall response rate (ORR) of 42% by a blinded ...
Broader community enrollment improves external validity by capturing patients with comorbidities and real-world treatment patterns, while familiarizing clinicians with toxicity management before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results